We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac.
- Authors
Omelchenko, V. O.; Kurochkina, Yu. D.; Fedorova, A. V.; Ovchinnikov, V. S.; Koval, V. V.; Bratko, I. V.; Letyagina, E. A.; Korolev, M. A.
- Abstract
The COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a "switch" to another genetically engineered drug in the patients with high risk of adverse COVID-19. In this study, we assessed the severity of immune response to SARS-CoV-2 antigens in rituximab-treated patients with rheumatoid arthritis vaccinated with the combined vector vaccine Gam-COVID-Vac. Insufficient formation of the humoral response and a high level of T-cell response to SARS-CoV-2 antigens in this group of patients were revealed. An imbalance of cellular and humoral response may play a role in more severe COVID-19 in rituximab-treated patients with rheumatoid arthritis.
- Subjects
HUMORAL immunity; COMBINED vaccines; RHEUMATOID arthritis; COVID-19 vaccines; RECOMBINANT drugs; T cells
- Publication
Bulletin of Experimental Biology & Medicine, 2024, Vol 176, Issue 6, p786
- ISSN
0007-4888
- Publication type
Article
- DOI
10.1007/s10517-024-06109-9